ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The Securities & Exchange Commission has charged a former executive of biotech firm Genta and two Genta stock owners with insider trading. According to a complaint filed in U.S. District Court for the District of New Jersey, Genta President Loretta M. Itri tipped off a friend about poor Phase III clinical trial results for Genasense, a melanoma treatment, a day before publicly releasing the results in 2009. The friend and an acquaintance sold their Genta shares for a gain of $139,000. Itri agreed to pay a $64,000 fine and will be barred from serving as an officer of a public firm for five years. The two others agreed to pay fines and return gains totaling $262,000. Genta filed for bankruptcy in 2012.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter